Affiliation:
1. VA Cooperative Studies Program Coordinating Center, Boston, MA 02111, USA
2. School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
Abstract
Often in the planning phase of a clinical trial, a researcher will need to choose between a standard versus weighted log-rank test (LRT) for investigating right-censored survival data. While a standard LRT is optimal for analyzing evenly distributed but distinct survival events (proportional hazards), an appropriately weighted LRT test may be better suited for handling non-proportional, delayed treatment effects. The “a priori” misspecification of this alternative may result in a substantial loss of power when determining the effectiveness of an experimental drug. In this paper, the standard unweighted and inverse log-rank tests (iLRTs) are compared with the multiple weight, default Max-Combo procedure for analyzing differential late survival outcomes. Unlike combination LRTs that depend on the arbitrary selection of weights, the iLRT by definition is a single weight test and does not require implicit multiplicity correction. Empirically, both weighted methods have reasonable flexibility for assessing continuous survival curve differences from the onset of a study. However, the iLRT may be preferable for accommodating delayed separating survival curves, especially when one arm finishes first. Using standard large-sample methods, the power and sample size for the iLRT are easily estimated without resorting to complex and timely simulations.
Subject
Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health
Reference104 articles.
1. Critical review of oncology clinical trial design under non-proportional hazards;Ananthakrishnan;Crit. Rev. Oncol. Hematol.,2021
2. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: Results of >2 years of follow-up;Fradet;Ann. Oncol.,2019
3. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial;Ascierto;Lancet Oncol.,2017
4. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer;Borghaei;N. Engl. J. Med.,2015
5. The asymptotic properties of nonparametric tests for comparing survival distributions;Schoenfeld;Biometrika,1981